Drug Profile
Research programme: systemic lupus erythematosus therapy - Tanox
Alternative Names: Systemic lupus erythematosus therapy research programme - Tanox; TNX-668Latest Information Update: 04 May 2007
Price :
$50
*
At a glance
- Originator Tanox
- Class
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 04 May 2007 No development reported - Preclinical for Systemic lupus erythematosus in USA (unspecified route)
- 18 Jan 2005 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)